URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit
Robbins LLPinforms stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025. UroGen engages in the development and commercialization of solutions for specialty cancers. The Company's lead pipeline product is UGN-102 (mitomycin), an intravesical solution […]